Revision history of "Autologous Mesenchymal stem cells transplantation of adipose origin for the treatment of corneal diseases" (Q3161553)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

22 March 2024

20 December 2023

12 June 2023

10 June 2023

4 August 2022

  • curprev 09:2009:20, 4 August 2022DG Regio talk contribs 71,735 bytes +48,897 Changed label, description and/or aliases in et, lt, hr, el, sk, fi, pl, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv, nl, fr, de, it, es, and other parts: Adding translations: et, lt, hr, el, sk, fi, pl, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv,

16 January 2022

17 December 2021

9 December 2021

4 December 2021

12 October 2021

  • curprev 17:0817:08, 12 October 2021DG Regio talk contribs 12,415 bytes +165 Changed label, description and/or aliases in en: translated_label
  • curprev 17:0817:08, 12 October 2021DG Regio talk contribs 12,250 bytes +2,250 Created claim: summary (P836): The objective of the study is to evaluate the safety, efficacy and tolerance of transplantation of an Advanced Therapy Medicine (ATMP). It is a single dose of adult stem cells derived from autologous adipose mesenchymal tissue (ADAS), cellularised in laminates for subjects with cornea defects. 3 groups will be included in the study: (1) ADAS transplantation only without support, (2) support transplant (decellularised human corneal sheet) without...

10 October 2021

9 October 2021

8 October 2021